Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 350

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 350
---
 and the preexisting shareholders of Kadimastem are currently anticipated to have the majority voting rights of the combined company. 2. Pro Forma Adjustments The Company is providing the unaudited pro forma condensed combined information for illustrative purposes only and such pro forma information does not represent the consolidated results or financial position of the Company had its acquisition of Kadimastem been completed as of the dates indicated. The companies may have performed differently had they been combined during the periods presented. Specifically, the unaudited pro forma condensed combined financial information does not reflect any cost savings, operating synergies, revenue enhancements or restructuring costs that the combined company may achieve or incur as a result of the acquisition. You should not rely on the unaudited pro forma condensed combined financial information as being indicative of the historical results that would have been achieved had the companies actually been combined during the periods presented. Further, the unaudited pro forma condensed combined financial information does not purport to project the future financial position or operating results of the combined company. The pro forma adjustments in the unaudited pro forma condensed combined balance sheet as of June 30, 2024 and statement of operations for the six months ended June 30, 2024 and twelve months ended as of December 31, 2023 are as follows: (A)To record gross proceeds of $3.2million received by NLS on October10, 2024, in connection with the sale of 806,452 common shares and warrants to purchase an additional 806,452 common shares, at a combined purchase price of $3.97, October Equity Purchase Agreement. The warrants have a term of five years and an exercise price of $4.25 per share adjusted to $3.10 upon execution of the December SPA agreed on January9, 2025 to satisfy the anti -dilutionprovision; (B)To record gross proceeds of $786,662 in connection with the sale of 81,944 common shares at a purchase price of $9.60 per share on July1, 2024; (C)To record gross proceeds of $500,000 in connection with issuance of 161,290 common shares issued in a private placement pursuant to December 2024 securities purchase agreement agreed on January9, 2025; (D)To record gross proceeds of CHF 153,145 (“Exercise Price in USD of $168,980”) in connection with the issuance of 191,431 common shares due to exercise of